Bioxyne Lands Aurora Cannabis as Manufacturing Client Across 3 Global Markets

Bioxyne secures manufacturing deal with global cannabis giant Aurora

Bioxyne Limited (ASX: BXN) has announced a Bioxyne Aurora Cannabis Manufacturing Agreement through its wholly owned subsidiary Breathe Life Sciences (BLS), partnering with Aurora Cannabis Inc. (NASDAQ/TSX: ACB), one of the world’s largest medical cannabis producers. Initial deliveries of medicinal cannabis oils have already been completed, with the partnership now expanding to include GMP-manufactured cannabis vapes for supply into Australian, UK and German markets. The 12-month rolling agreement, which automatically renews unless terminated with 6 months’ notice, validates BXN’s pharmaceutical-grade manufacturing credentials on the global stage and provides immediate revenue generation from a top-tier international counterparty.

This partnership elevates Bioxyne from a domestic manufacturer to a supplier for a publicly listed global cannabis leader, opening material international revenue channels across three highly regulated medical cannabis markets.

What the agreement covers

The manufacturing agreement operates across two product phases and three geographic markets. Initial deliveries of medicinal cannabis oils to the Australian market have been completed, with the partnership now expanding to GMP-manufactured cannabis vapes for distribution across Australia, the United Kingdom and Germany. Discussions are progressing regarding additional product lines beyond vapes, with the onboarding process for new products already commenced.

The expansion from oils to vapes and multi-market distribution demonstrates scalable revenue potential beyond a single product line, with Aurora’s commitment to additional products signalling long-term supply chain integration rather than a one-off manufacturing arrangement.

Why GMP certification matters for cannabis investors

Good Manufacturing Practice (GMP) certification represents pharmaceutical-grade manufacturing standards that create significant competitive barriers in regulated medical cannabis markets. GMP certification requires strict quality control systems, validated manufacturing processes, and comprehensive documentation protocols that meet the same standards applied to conventional pharmaceutical production.

This certification is essential for access to medical cannabis markets in the UK, Germany and Australia, where regulatory frameworks prohibit the sale of medical cannabis products manufactured without GMP accreditation. The certification process itself requires substantial capital investment, technical expertise, and regulatory compliance capabilities that many cannabis manufacturers cannot achieve, creating a natural barrier to entry that protects margin profiles in medical markets.

For Aurora Cannabis to select BLS as a manufacturing partner, BXN’s facilities must meet the same GMP standards Aurora maintains in its own Canadian and German production centres. This positions Bioxyne as a preferred supplier in high-margin, regulated medical segments rather than competing in commoditised recreational markets where price competition erodes profitability.

Management commentary signals growth ambitions

Executive commentary from both companies frames the partnership as a strategic relationship with expansion potential beyond the initial product scope.

Sam Watson, Bioxyne Chief Executive Officer

“This partnership with Aurora represents a significant milestone for BLS as we expand our manufacturing capabilities. We are excited about the potential of our broader product portfolio across multiple international markets. This agreement validates our pharmaceutical manufacturing expertise and positions us well for growth.”

Alex Miller, Executive Vice President, Operations & Supply Chain for Aurora, emphasised the quality and scale considerations behind the partnership selection: “As a global leader in medical cannabis, we’re focused on building a resilient, high-quality supply chain across key international markets. BLS brings strong GMP-manufacturing capabilities that complement our scale, regulatory scrutiny and commitment to delivering high quality medical cannabis products to patients.”

The partnership represents mutual validation. Aurora gains manufacturing diversification and supply chain resilience across three international markets, whilst Bioxyne secures credibility as a globally recognised manufacturer capable of serving publicly listed pharmaceutical-grade cannabis producers. The ongoing discussions regarding additional product lines indicate both parties view this as a platform for expanding commercial collaboration rather than a static supply arrangement.

Bioxyne’s global footprint

BLS operates a multi-jurisdictional infrastructure that reduces execution risk for international manufacturing partnerships:

• Sydney: Corporate head office
• Queensland, Australia: Licensed manufacturing, warehousing, import/export, sales and distribution
• Nagoya, Japan: Operations and distribution centre
• Manchester, UK: Manufacturing and distribution facility
• Prague, Czechia: European operations base

BLS holds licensing for manufacturing, wholesaling, import and export of controlled substances including Schedule 3, 4, 8 and 9 classifications, covering medicinal cannabis, Psilocybin and MDMA. The company’s Dr Watson® brand operates in the UK, Japan, Australia and New Zealand, demonstrating existing international consumer reach across cannabis-based food supplements, functional mushrooms and prescription medicines.

This established infrastructure across multiple jurisdictions positions BXN to service the Aurora contract without requiring new facility construction or regulatory approvals, whilst providing a platform for additional international manufacturing agreements with other pharmaceutical-grade cannabis companies.

What this means for BXN shareholders

The Aurora partnership materially strengthens Bioxyne’s investment profile across several dimensions:

1. Revenue diversification with creditworthy counterparty: Aurora’s listing on NASDAQ and TSX provides financial transparency and creditworthiness that de-risks BXN’s revenue base. The 12-month rolling term with automatic renewal provides medium-term revenue visibility.

2. Validation of manufacturing capabilities: Selection by a global cannabis leader operating GMP-certified facilities in Canada and Germany validates BXN’s technical capabilities and positions the company to compete for additional international manufacturing contracts.

3. Geographic revenue expansion: The three-market footprint (Australia, UK, Germany) diversifies BXN’s revenue exposure beyond domestic Australian sales, accessing larger addressable markets with higher medical cannabis adoption rates.

4. Near-term expansion catalysts: The confirmed expansion to cannabis vapes and ongoing discussions regarding additional product lines provide visible near-term catalysts for revenue growth from the existing partnership, rather than requiring new contract wins.

The immediate completion of initial deliveries confirms this is not a future-dated agreement but an active, revenue-generating partnership. For a company of BXN’s scale, securing a contract manufacturing relationship with a NASDAQ-listed international cannabis producer represents a material validation of both technical capabilities and commercial positioning within pharmaceutical-grade cannabis supply chains.

Want the Next Cannabis Breakout in Your Inbox?

Join 20,000+ investors getting FREE breaking ASX news delivered within minutes of release, complete with expert analysis. Click the “Free Alerts” button at Big News Blast to receive real-time alerts the moment market-moving announcements hit the wire across Healthcare, Tech, Finance and more.